Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam PK and DDI with Midazolam in Healthy Volunteers
NCT03988907Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of risdiplam in spinal muscular atrophy (SMA) (2 arms), sponsored by Roche. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 15, Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Concentration at Day 15 and 1 more. Started Jun 2019; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03988907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988907.